Exact Sciences Stock 8-Day Winning Spree: Stock Climbs 51%
Exact Sciences (EXAS) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 51% return. The company has gained about $6.5 Bil in value over the last 8 days, with its current market capitalization at about $19 Bil. The stock remains 80.5% above its value at the end of 2024. This compares with year-to-date returns of 15.8% for the S&P 500.
Exact Sciences’ recent streak was ignited by Abbott Laboratories’ definitive agreement to acquire the cancer diagnostics leader for $105 per share, valuing the deal at $21 billion. This strategic takeover, following robust Q3 earnings and promising product pipeline developments like Cancerguard and Oncoguard Liver, underscores the surging value of its innovative screening technologies.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is a near-equal mix of good and bad in EXAS stock given its overall Moderate operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Unattractive (see Buy or Sell EXAS).
For quick background, EXAS provides cancer screening and diagnostic tests, including a non-invasive stool-based DNA test for colorectal cancer and gene expression tests for breast, prostate, and colon cancers.
Comparing EXAS Stock Returns With The S&P 500
The following table summarizes the return for EXAS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | EXAS | S&P 500 |
|---|---|---|
| 1D | 0.3% | 0.7% |
| 8D (Current Streak) | 51.4% | 1.2% |
| 1M (21D) | 60.3% | -1.1% |
| 3M (63D) | 116.1% | 4.8% |
| YTD 2025 | 80.5% | 15.8% |
| 2024 | -24.0% | 23.3% |
| 2023 | 49.4% | 24.2% |
| 2022 | -36.4% | -19.4% |
However, big gains can follow sharp reversals – but how has EXAS behaved after prior drops? See EXAS Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 136 S&P constituents with 3 days or more of consecutive gains and 8 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 20 | 7 |
| 4D | 94 | 0 |
| 5D | 14 | 0 |
| 6D | 3 | 0 |
| 7D or more | 5 | 1 |
| Total >=3 D | 136 | 8 |
Key Financials for Exact Sciences (EXAS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $2.5 Bil | $2.8 Bil |
| Operating Income | $-214.3 Mil | $-179.1 Mil |
| Net Income | $-204.1 Mil | $-1.0 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $811.1 Mil | $850.7 Mil |
| Operating Income | $-2.1 Mil | $-25.0 Mil |
| Net Income | $-1.2 Mil | $-19.6 Mil |
While EXAS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.